Sustained glucocorticoid exposure recruits cortico-limbic CRH signaling to modulate endocannabinoid function

Psychoneuroendocrinology

Volumn 66, Issue , 2016, Pages 151-158

  Gray, J Megan ^a,b   Wilson, Christopher D ^c   Lee, Tiffany T Y ^a,d   Pittman, Quentin J ^a,b   Deussing, Jan M ^e   Hillard, Cecilia J ^f   McEwen, Bruce S ^c   Schulkin, Jay ^g   Karatsoreos, Ilia N ^h   Patel, Sachin ⁱ   Hill, Matthew N ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c ROCKEFELLER UNIVERSITY   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^f MEDICAL COLLEGE OF WISCONSIN   (United States)

^g GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h WASHINGTON STATE UNIVERSITY   (United States)

ⁱ VANDERBILT UNIVERSITY   (United States)

Author keywords

2 Arachidonoylglycerol(2 AG); Corticotropin releasing; Fatty acid amide hydrolase(FAAH); Glucocorticoid; Hormone receptor 1 (CRHR1); HPA axis; Restraint

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; FATTY ACID AMIDASE; GLUCOCORTICOID; MESSENGER RNA; ENDOCANNABINOID;

ADULT; AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; HORMONE DETERMINATION; HYDROLYSIS; MALE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; STRESS; UPREGULATION; AMYGDALA; ANIMAL; C57BL MOUSE; DRUG EFFECTS; EXERCISE; LIMBIC SYSTEM; MENTAL STRESS; METABOLISM; MOUSE; PHYSIOLOGY; PSYCHOLOGY; SPRAGUE DAWLEY RAT; TRANSGENIC MOUSE;

AMYGDALA; ANIMALS; CORTICOTROPIN-RELEASING HORMONE; ENDOCANNABINOIDS; GLUCOCORTICOIDS; LIMBIC SYSTEM; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; RESTRAINT, PHYSICAL; SIGNAL TRANSDUCTION; STRESS, PSYCHOLOGICAL;

EID: 84960901292     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2016.01.004     Document Type: Article

References (49)

1. Bangasser D.A., Reyes B.A.S., Piel D., Garachh V., Zhang Y., Plona Z.M., Bockstaele E.J., Van Beck S.G., Valentino R.J. Increased vulnerability of the brain norepinephrine system of females to corticotropin-releasing factor overexpression. Mol. Psychiatry 2013, 18:166-173.
2. Bortolato M., Mangieri R.A., Fu J., Kim J.H., Arguello O., Duranti A., Tontini A., Mor M., Tarzia G., Piomelli D. Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol. Psychiatry 2007, 62:1103-1110.
3. Bowles N.P., Hill M.N., Bhagat S.M., Karatsoreos I.N., Hillard C.J., McEwen B.S. Chronic, noninvasive glucocorticoid administration suppresses limbic endocannabinoid signaling in mice. Neuroscience 2012, 204:83-89.
4. Dedic N., Touma C., Romanowski C.P., Schieven M., Kuhne C., Albeitner M., Lu A., Holsboer F., Wurst W., Kimura M., Deussing J.M. Assessing behavioral effects of chronic HPA axis activation using conditional CRH-overexpressing mice. Cell Mol. Neurobiol. 2012, 32:815-828.
5. Dubreucq S., Matias I., Cardinal P., Häring M., Lutz B., Marsicano G., Chaouloff F. Genetic dissection of the role of cannabinoid type-1 receptors in the emotional consequences of repeated social stress in mice. Neuropsychopharmacology 2012, 37:1885-1900.
6. Evanson N.K., Tasker J.G., Hill M.N., Hillard C.J., Herman J.P. Fast feedback inhibition of the HPA axis by glucocorticoids is mediated by endocannabinoid signaling. Endocrinology 2010, 151:4811-4819.
7. Gray J.M., Chaouloff F., Hill M.N. To stress or not to stress: a question of models. Curr. Protoc. Neurosci. 2015, 70(8.33). 1-8.33.22.
8. Gray J.M., Vecchiarelli H., Morena M., Lee T.T.Y., Hermanson D.J., Kim A.B., McLaughlin R.J., Hassan K.I., Kühne C., Wotjak C.T., Deussing J.M., Patel S., Hill M.N. Corticotropin-releasing hormone drives anandamide hydrolysis in the amygdala to promote anxiety. J. Neurosci. 2015, 35:3879-3892.
9. Gray J.M., Vecchiarelli H., Hill M.N. Endocannabinoid signaling and synaptic plasticity during stress. Synaptic Stress and Pathogenesis of Neuropsychiatric Disorders 2014, 99-124. Springer Inc, New York. M. Popoli, D. Diamond, G. Sanacora (Eds.).
10. Gray M., Bingham B., Viau V. A comparison of two repeated restraint stress paradigms on hypothalamic-pituitary-adrenal axis habituation, gonadal status and central neuropeptide expression in adult male rats. J. Neuroendocrinol. 2010, 22:92-101.
11. Gunduz-Cinar O., Hill M.N., McEwen B.S., Holmes A. Amygdala FAAH and anandamide: mediating protection and recovery from stress. Trends Pharmacol. Sci. 2013, 11:637-644.
12. Hill M.N., Ho W.S., Meier S.E., Gorzalka B.B., Hillard C.J. Chronic corticosterone treatment increases the endocannabinoid 2-arachidonoylglycerol in the rat amygdala. Eur. J. Pharmacol. 2005, 528:99-102.
13. Hill M.N., Karatsoreos I.N., Hillard C.J., McEwen B.S. Rapid elevations in limbic endocannabinoid content by glucocorticoid hormones in vivo. Psychoneuroendocrinology 2010, 35:1333-1338.
14. Hill M.N., Kumar S., Filipski S.B., Iverson M., Stuhr K.L., Keith J.M., Cravatt B.F., Hillard C.J., Chattarji S., McEwen B.S. Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructure. Mol. Psychiatry 2013, 18:1125-1135.
15. Hill M.N., McLaughlin R.J., Bingham B., Shrestha L., Lee T.T.Y., Gray J.M., Hillard C.J., Gorzalka B.B., Viau V. Endogenous cannabinoid signaling is essential for stress adaptation. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:9406-9411.
16. Hill M.N., McLaughlin R.J., Morrish A.C., Viau V., Floresco S.B., Hillard C.J., Gorzalka B.B. Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology 2009, 34:2733-2745.
17. Hill M.N., Mclaughlin R.J., Pan B., Fitzgerald M.L., Christopher J., Lee T.T., Karatsoreos I.N., Mackie K., Viau V., Virginia M., Mcewen B.S., Liu Q., Gorzalka B.B., Hillard C.J. Recruitment of prefrontal cortex endocannabinoid signaling by glucocorticoids contributes to termination of the stress response. J. Neurosci. 2011, 31:10506-10515.
18. Hill M.N., Tasker J.G. Endocannabinoid signaling, glucocorticoid-mediated negative feedback, and regulation of the hypothalamic-pituitary-adrenal axis. Neuroscience 2012, 204:5-16.
19. Hillard C.J., Weinlander K.M., Stuhr K.L. Contributions of endocannabinoid signaling to psychiatry disorders in humans: genetic and biochemical evidence. Neuroscience 2012, 204:207-229.
20. Hermanson D.J., Hartley N.D., Gamble-George J., Brown N., Shonesy B.C., Kingsley P.J., Colbran R.J., Reese J., Marnett L.J., Patel S. Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation. Nat. Neurosci. 2013, 16:1291-1298.
21. Jaferi A., Bhatnagar S. Corticotropin-releasing hormone receptors in the medial prefrontal cortex regulate hypothalamic-pituitary-adrenal activity and anxiety-related behavior regardless of prior stress experience. Brain Res. 2007, 1186:212-223.
22. Jennings E.M., Okine B.N., Olango W.M., Roche M., Finn D.P. Repeated forced swim stress differently affects formalin-evoked nociceptive behavior and the endocannabinoid system in stress normo-responsive and stress hyper-responsive rat strains. Prog. Neuropsychopharmacol. Biol. Psychiatry 2016, 64:181-189.
23. Judd L.L., Schettler P.J., Brown E.S., Wolkowitz O.M., Sternberg E.M., Bender B.G., Bulloch K., Cidlowski J.A., de Kloet E.R., Fardet L., Joels M., Leung D.Y., McEwen B.S., Roozendaal B., Van Rossum E.F., Ahn J., Brown D.W., Plitt A., Singh G. Adverse consequences of glucocorticoid medication: Psychological, cognitive and behavioral effects. Am. J. Psychiatry 2014, 171:1045-1051.
24. Karst H., Berger S., Erdmann G., Schütz G., Joëls M. Metaplasticity of amygdalar responses to the stress hormone corticosterone. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:14449-14454.
25. Kathuria S., Gaetani S., Fegley D., Valiño F., Duranti A., Tontini A., Mor M., Tarzia G., La Rana G., Calignano A., Giustino A., Tattoli M., Palmery M., Cuomo V., Piomelli D. Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 2003, 9:76-81.
26. Kinlein S.A., Wilson C.D., Karatsoreos I.N. Dysregulated hypothalamic-pituitary-adrenal axis function contributes to altered endocrine and neurobehavioral responses to acute stress. Front. Psychiatry 2015, 6:31.
27. Liston C., Miller M.M., Goldwater D.S., Radley J.J., Rocher A.B., Hof P.R., Morrison J.H., McEwen B.S. Stress-induced alterations in prefrontal cortical dendritic morphology predict selective impairments in perceptual attentional set-shifting. J. Neurosci. 2006, 26:7870-7874.
28. Lomazzo E., Bindila L., Remmers F., Lerner R., Schwitter C., Hoheisel U., Lutz B. Therapeutic potential of inhibitors of endocannabinoid degradation for the treatment of stress-related hyperalgesia in an animal model of chronic pain. Neuropsychopharmacology 2015, 40:488-501.
29. Lu A., Steiner M.A., Whittle N., Vogl A.M., Walser S.M., Ableitner M., Refojo D., Ekker M., Rubenstein J.L., Stalla G.K., Singewald N., Holsboer F., Wotjak C.T., Wurst W., Deussing J.M. Conditional CRH overexpressing mice: an animal model for stress-elicited pathologies and treatments that target the central CRH system. Mol. Psychiatry 2008, 13:1028-1042.
30. Makino S., Gold P.W., Schulkin J. Corticosterone effects on corticotropin-releasing hormone mRNA in the central nucleus of the amygdala and the parvocellular region of the paraventricular nucleus of the hypothalamus. Brain Res. 1994, 640:105-112.
31. Makino S., Gold P.W., Schulkin J. Effects of corticosterone on CRH mRNA and content in the bed nucleus of the stria terminalis; comparison with the effects in the central nucleus of the amygdala and the paraventricular nucleus of the hypothalamus. Brain Res. 1994, 657:141-149.
32. Makino S., Shibasaki T., Yamauchi N., Nishioka T., Mimoto T., Wakabayashi I., Gold P.W., Hashimoto K. Psychological stress increased corticotropin-releasing hormone mRNA and content in the central nucleus of the amygdala but not in the hypothalamic paraventricular nucleus in the rat. Brain Res 1999, 850:136-143.
33. McLaughlin R.J., Hill M.N., Bambico F.R., Stuhr K.L., Gobbi G., Hillard C.J., Gorzalka B.B. Prefrontal cortical anandamide signaling coordinates coping responses to stress through a serotonergic pathway. Eur. Neuropsychopharmacol. 2012, 22:664-671.
34. McLaughlin R.J., Hill M.N., Gorzalka B.B. A critical role for prefrontocortical endocannabinoid signaling in the regulation of stress and emotional behavior. Neurosci. Biobehav. Rev. 2014, 42:116-131.
35. Merali Z., Anisman H., James J.S., Kent P., Schulkin J. Effects of corticosterone on corticotrophin-releasing hormone and gastrin-releasing peptide release in response to an aversive stimulus in two regions of the forebrain (central nucleus of the amygdala and prefrontal cortex). Eur. J. Neurosci. 2008, 28:165-172.
36. Miguel T.T., Gomes K.S., Nunes-de-Souza R.L. Tonic modulation of anxiety-like behavior by corticotropin-releasing factor (CRF) type 1 receptor (CRF1) within the medial prefrontal cortex (mPFC) in male mice: role of protein kinase A (PKA). Horm. Behav 2014, 66:247-256.
37. Mizoguchi K., Ishige A., Aburada M., Tabira T. Chronic stress attenuates glucocorticoid negative feedback: involvement of the prefrontal cortex and hippocampus. Neuroscience 2003, 119:887-897.
38. Morena M., Patel S., Bains J.S., Hill M.N. Neurobiological interactions between stress and the endocannabinoid system. Neuropsychopharmacology 2016, 41:80-102.
39. Nemeroff C., Widerlove E., Bissette G., Walleus H., Karlsson I., Eklund K., Kilts C., Loosen P., Vale V. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 1984, 226:1342-1344.
40. Nemeroff C.B., Owens M.J., Bissette G., Andorn A.C., Stanley M. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch. Gen. Psychiatry 1988, 45:577-579.
41. Patel S., Roelke C.T., Rademacher D.J., Hillard C.J. Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling. Eur. J. Neurosci. 2005, 21:1057-1069.
42. Rademacher D.J., Meier S.E., Shi L., Ho W.-S.V., Jarrahian A., Hillard C.J. Effects of acute and repeated restraint stress on endocannabinoid content in the amygdala, ventral striatum, and medial prefrontal cortex in mice. Neuropharmacology 2008, 54:108-116.
43. Refojo D., Schweizer M., Kuehne C., Ehrenberg S., Thoeringer C., Vogl A.M., Dedic N., Schumacher M., von Wolff G., Avrabos C., Touma C., Engblom D., Schütz G., Nave K.-A., Eder M., Wotjak C.T., Sillaber I., Holsboer F., Wurst W., Deussing J.M. Glutamatergic and dopaminergic neurons mediate anxiogenic and anxiolytic effects of CRHR1. Science 2011, 333:1903-1907.
44. Rossi S., Chiara V., De Musella A., Sacchetti L., Cantarella C., Castelli M., Cavasinni F., Motta C., Studer V., Bernardi G., Cravatt B.F., Maccarrone M., Usiello A., Centonze D. Preservation of striatal cannabinoid CB1 receptor function correlates with the antianxiety effects of fatty acid amide hydrolase inhibition. Mol. Pharmacol. 2010, 78:260-268.
45. Silberstein S., Vogl M., Refojo D., Senin S., Wurst W., Holsboer F., Deussing J.M., Arzt E. Amygdaloid pERK1/2 in corticotropin-releasing hormone overexpressing mice under basal and acute stress conditions. Neuroscience 2009, 159:610-617.
46. Swanson L., Simmons D. Differential steroid hormone and neural influences on peptide mRNA levels in CRH cells of the paraventricular nucleus: a hybridization histochemical study in the rat. J. Comp. Neurol. 1989, 285:413-435.
47. Wang M., Hill M.N., Zhang L., Gorzalka B.B., Hillard C.J., Alger B.E. Acute restraint stress enhances hippocampal endocannabinoid function via glucocorticoid receptor activation. J. Psychopharmacol. 2012, 26:56-70.
48. Warden M.R., Selimbeyoglu A., Mirzabekov J.J., Lo M., Thompson K.R., Kim S.Y., Adhikari A., Tye K.M., Frank L.M., Deisseroth K. A prefrontal cortex-brainstem neuronal projection that controls response to behavioral challenge. Nature 2012, 492(7429):428-432.
49. Zobel A.W., Nickel T., Ku H.E., Ackl N., Sonntag A., Ising M., Holsboer F. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatr. Res. 2000, 34:171-181.